clinical trial · NCT05154487
A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
GOG Foundation·phase2·active not recruiting·n = 51
Endometroid Endometrial CancerAlpelisib PillFulvestrant injection
brief summary
This is a 2 stage multi-center study designed to evaluate the efficacy of the combination of alpelisib and fulvestrant in patients with PIK3CA-mutated ER-positive endometrioid endometrial cancers by estimating the objective response rate (ORR). Treatment will continue until either unacceptable toxicity, progression of disease, or investigator/patient request for withdrawal.
started
Sep 11, 2024
primary completion
May 1, 2028
completion
Nov 1, 2028
last updated
Mar 3, 2026
official title
Phase 2 Study of Alpelisib and Fulvestrant for PIK3CA-mutated Estrogen Receptor (ER)-Positive Endometrioid Endometrial Cancers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol